275 related articles for article (PubMed ID: 12879454)
41. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y
FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464
[TBL] [Abstract][Full Text] [Related]
42. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R
Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338
[TBL] [Abstract][Full Text] [Related]
43. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.
Yamamoto M; Kurosu T; Kakihana K; Mizuchi D; Miura O
Biochem Biophys Res Commun; 2004 Jul; 319(4):1272-5. PubMed ID: 15194504
[TBL] [Abstract][Full Text] [Related]
44. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA
Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728
[TBL] [Abstract][Full Text] [Related]
45. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway.
Santos SC; Lacronique V; Bouchaert I; Monni R; Bernard O; Gisselbrecht S; Gouilleux F
Oncogene; 2001 Apr; 20(17):2080-90. PubMed ID: 11360192
[TBL] [Abstract][Full Text] [Related]
46. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of CML model cell lines and imatinib mesylate response: determinants of signaling profiles.
Wetzel R; Goss VL; Norris B; Popova L; Melnick M; Smith BL
J Immunol Methods; 2005 Oct; 305(1):59-66. PubMed ID: 16169003
[TBL] [Abstract][Full Text] [Related]
48. Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a).
Håkansson P; Lassen C; Olofsson T; Baldetorp B; Karlsson A; Gullberg U; Fioretos T
Leukemia; 2004 Mar; 18(3):538-47. PubMed ID: 14712293
[TBL] [Abstract][Full Text] [Related]
49. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
50. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Møller GM; Frost V; Melo JV; Chantry A
FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
[TBL] [Abstract][Full Text] [Related]
51. Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate.
Park J; Kim S; Oh C; Yoon SS; Lee D; Kim Y
Biochem Biophys Res Commun; 2005 Oct; 336(3):942-51. PubMed ID: 16157305
[TBL] [Abstract][Full Text] [Related]
52. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.
Mencalha AL; Du Rocher B; Salles D; Binato R; Abdelhay E
Cancer Chemother Pharmacol; 2010 May; 65(6):1039-46. PubMed ID: 19701750
[TBL] [Abstract][Full Text] [Related]
53. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
[TBL] [Abstract][Full Text] [Related]
54. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
[TBL] [Abstract][Full Text] [Related]
55. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
[TBL] [Abstract][Full Text] [Related]
56. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
[TBL] [Abstract][Full Text] [Related]
57. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
59. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
Okuda K; Golub TR; Gilliland DG; Griffin JD
Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
[TBL] [Abstract][Full Text] [Related]
60. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
Mizutani T; Kondo T; Darmanin S; Tsuda M; Tanaka S; Tobiume M; Asaka M; Ohba Y
Clin Cancer Res; 2010 Aug; 16(15):3964-75. PubMed ID: 20670950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
